In PR+ERα+ breast, endometrial, and ovarian cancer cell lines, high doses of the progestin R5020 upregulated PR expression at the transcriptional and translational levels and the effect was reversed by the addition of the antagonist RU 486 (Diep et al., 2016). This evidence concerns the gene PGR and ovarian cancer.